Skip to content
Screener

Trevi Therapeutics, Inc. TRVI Q3 2025 earnings

Reported November 13, 2025 · After market close

EPS-$0.08Beat by $0.02
EPS estimate-$0.10

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.13

Financials

Q3 2025

Income statement

See full
Operating income-$13.9M+1.2%
Net income-$11.8M+10.9%
EPS (diluted)-$0.08+38.5%

Balance sheet

See full
Cash & equivalents$56.9M+254%
Total debt$823.0K-30.0%
Total equity$189.8M+222%
Total assets$199.4M+189%

Cash flow

See full
Operating cash flow-$10.9M-13.9%
CapEx$12.0K—
Free cash flow-$10.9M-14.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.11B+230%
Enterprise value$1.06B+228%

Returns & leverage

See full
Return on equity-36.9%-10.2pp
Debt / equity0×0.0×
Current ratio21.9×+14.6×

FAQ

When did Trevi Therapeutics, Inc. report Q3 2025 earnings?
Trevi Therapeutics, Inc. (TRVI) reported Q3 2025 earnings on November 13, 2025 after market close.
What were Trevi Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Trevi Therapeutics, Inc. reported eps of $-0.08 for Q3 2025.
Did Trevi Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.10 by $0.02.
How did Trevi Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 38.5% from $-0.13.
Where can I find Trevi Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-280149) and the 10-Q periodic report (0001193125-25-280166) directly on SEC EDGAR. The filing index links above go to sec.gov.